RALEIGH, N.C., Feb. 7, 2017 /PRNewswire/ -- Executives from Innovate Biopharmaceuticals Inc., which has drug candidates entering Phase 3 and Phase 2 clinical trials, respectively, for the treatments of celiac disease and ulcerative colitis, will be in New York Feb. 13-14, meeting with potential investors at the BIO CEO & Investor Conference. Innovate's presentation is on Monday, Feb. 13, at 2 p.m. EST in the Conrad Room at The Waldorf Astoria.
Interested investors and licensing partners can email the company to schedule meetings: investor.relations@innovatebiopharma.com.
Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines. Innovate is also developing therapeutics for unmet needs with global impact and for orphan indications.
The company's lead drug candidate for celiac disease, larazotide acetate (INN-202), begins Phase 3 clinical trials in 2017. Larazotide, a novel oral peptide, has been studied in more than 800 patients with results that consistently reduced clinical symptoms of celiac disease. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions."
Innovate's second therapeutic, INN-108, enters Phase 2 trials in 2017. INN-108 is a small molecule for the treatment of an adult orphan indication and for mild to moderate ulcerative colitis. INN-108 is a prodrug that only becomes activated in the colon. An oral liquid formulation is also in development for pediatric and elderly patients.
Licensing opportunities for these drugs are available outside the U.S.
Forward Looking Statements
This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, which are subject to risks and uncertainties that could cause actual results to differ materially. Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements.
SOURCE Innovate Biopharmaceuticals Inc.